Indian pharma company begins human trials for COVID-19 vaccine

Coronavirus Test Sample
Coronavirus File Photo (Photo Credit: Time Magazine)

Indian pharmaceutical company, Zydus, said on Wednesday it has started human studies for its potential COVID-19 vaccine.

The first dosage of its plasmid DNA vaccine ZyCoV-D was administered to a human test subject on Wednesday, the company said in a statement.

The vaccine elicited a strong immune response during trials in animal species including mice, rats, guinea pigs and rabbits.

No safety concerns were observed.

“In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic,’’ Zydus said.

The company said the DNA vaccine platform it had developed could be used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.

India, along with several other countries, has been fast-tracking and supporting the development of a Covid-19 vaccine as the numbers of infections and deaths swell.

Currently India ranks third after the U.S. and Brazil among countries worst hit by the pandemic, with 936,181 infections and a death toll of 24,209 officially confirmed, according to the latest Health Ministry data.

Several regions in India have announced fresh lockdowns, including IT hub Bangalore, as cases continue to spiral.

Nearly 30,000 new cases and 582 deaths were reported on Tuesday.



PT Mag Campaign AD

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.

Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.


TEXT AD: To advertise here . Call Willie +2347088095401...

BE THE FIRST TO KNOW! Subscribe to our newsletter

* indicates required


Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application